MedWatch

Covid vaccine race lights fire under GSK boss as RSV battle intensifies

GSK Plc is planning to launch a Covid shot that comes almost two years after Pfizer Inc. took the world by storm. For Phil Dormitzer, it’s a reminder of why he was hired at the UK drugmaker: to help return its immunization business to the top after it stumbled during the pandemic.

Photo: Jens Dresling

Phil Dormitzer, who left Pfizer to become GSK’s global vaccine research chief, will need to move beyond the Covid shot and deliver some breakthroughs to challenge his former employer and other rivals. The pressure is on as the British company prepares to spin off its consumer unit this month.

“The focus on vaccines is huge right now,” Dormitzer said in an interview from outside Boston, where he’s based. “After the separation of the consumer-health business, it will be an even more prominent part of the overall organization.”

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs